NeuBase Therapeutics Inc
F:O7PA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Element Fleet Management Corp
TSX:EFN
|
CA |
|
Jensen-Group NV
XBRU:JEN
|
BE |
|
Gaia Inc
NASDAQ:GAIA
|
US |
|
ZheJiangTailin Bioengineering Co Ltd
SZSE:300813
|
CN |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its Industry Average (6.2), the stock would be worth €0 (100% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | €0.16 |
0%
|
| Industry Average | 6.2 | €0 |
-100%
|
| Country Average | 3 | €0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
NeuBase Therapeutics Inc
F:O7PA
|
107.5m EUR | 0 | -9.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.5B USD | 7 | 88.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.3B USD | 6.3 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD | 6.2 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 8.7 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 4 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 11.4 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 3.6 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 |
Market Distribution
Other Multiples
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
